Jake Micallef

Dr. Jake Micallef, Ph.D., is the Chief Scientific Officer of VolitionRX Limited. He is an experienced scientific executive with expertise in research and development, and in the management of early-stage biotechnical companies, including the manufacture of biotechnology products and the establishment of manufacturing operations. Dr. Micallef gained this experience while working for the World Health Organization, or WHO, over a 10-year period from 1985. While working for the WHO, Dr. Micallef developed new diagnostic products in the areas of reproductive health and cancer. In 1990, he commenced development of a new diagnostic technology platform for WHO, which was launched in 1992 and supported 13 tests. Dr. Micallef also initiated and implemented in-house manufacture — previously outsourced to Abbott Diagnostics Inc. — and worldwide distribution of these products for WHO. In 1990, he started a not-for-profit WHO company, Immunometrics Ltd., which marketed and distributed those diagnostic products worldwide. In 1999, Dr. Micallef studied for an MBA and went on to co-found Gene Expression Technologies in 2001, where he successfully lead the development of the chemistry of the GeneICE technology and implemented the manufacture of GeneICE molecules. He also played a major role in business development and procured a GeneICE contract with Bayer Pharmaceuticals. From 2004 to 2007, he taught science and enterprise to science research workers from four universities at Cass Business School before joining Cronos Therapeutics in 2004. In 2006, Cronos was listed in the U.K. on AIM becoming ValiRx. Dr. Micallef continued to work as Technical Officer for ValiRx, where he in-licensed the HyperGenomics and Nucleosomics technologies, and co-founded ValiBIO SA, which is now Belgian Volition SA, a subsidiary of Singapore Volition. Dr. Micallef was educated at King’s College London, earning a B.S. in biology and chemistry, and a Ph.D. in physical chemistry; St Thomas’ Hospital Medical School, London, earning an M.S. in chemical pathology; and Imperial College Management School, earning an MBA.